National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
2,051 of 2,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
3,257 total, page 59 of 66
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
NCT00005655
A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)
NCT00001938
Bone Mineral Density and Subsequent Cancer Risk
NCT00340262
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
NCT00006213
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
NCT00005811
BMS-214662 in Treating Patients With Solid Tumors
NCT00005973
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
NCT00004892
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
NCT00005982
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
NCT00004853
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
NCT00004635
Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria
NCT00004988
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
NCT00005942
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00005838
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
NCT00004146
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
NCT00005818
Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)
NCT00019955
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
NCT00004244
Genetic Component of Handedness
NCT00005003
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
NCT00020111
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
NCT00005604
Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
NCT00005094
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
NCT00020072
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00005817
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
NCT00005831
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
NCT00019864
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
NCT01989572
Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial
NCT00339950
Susceptibility to Breast Cancer
NCT00004565
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
NCT00004931
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
NCT00005064
Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2
NCT00004883
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
NCT00005085
Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
NCT00005067
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
NCT00004547
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
NCT00005065
Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
NCT00004859
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
NCT00005039
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
NCT00020007
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
NCT00004919
Vinorelbine and XR9576 to Treat Cancer
NCT00001944
Voriconazole to Treat Fungal Infections
NCT00001940
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
NCT00004918
Anti-Tac for Treatment of Leukemia
NCT00001941
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
NCT00019682
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
NCT00004262
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
NCT00006364
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
NCT00001937
Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00004101
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NCT00005036
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Cancer Institute (NCI): open-pipeline peers nationwide
Peers matched on 3,257 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Cancer Institute (NCI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3,257 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- M.D. Anderson Cancer Center · 2,692 trials · 20% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Abiomed · 10% recruiting · 20 trials
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
Related
What to do with this National Cancer Institute (NCI) page
3,257 registered trials is a research-attention snapshot, not an endorsement of National Cancer Institute (NCI) or any single study.
- 326 of National Cancer Institute (NCI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Malignant Solid Neoplasm is the condition National Cancer Institute (NCI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Cancer Institute (NCI) pipeline card: 3,257 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.